OncBioMune to investigate new prostate cancer drug in Phase II trial
OncBioMune Pharmaceuticals has reported an ongoing review of its Phase II clinical trial protocol by the regulatory committee at Beth Israel Deaconess Medical Centre / Harvard Medical School in the US for evaluation of ProscaVax to treat early stage …
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news
More News: Cancer | Cancer & Oncology | Clinical Trials | Harvard | Israel Health | Middle East Health | Pharmaceuticals | Prostate Cancer